Keyphrases
Patient-centered
100%
Pre-exposure Prophylaxis (PrEP)
100%
Individuals at Risk
100%
Narrative Review
100%
Safety Profile
28%
Personalization
28%
Safety Concerns
14%
Highly Effective
14%
Phase II Study
14%
Comprehensive Evaluation
14%
Randomized Double-blind
14%
Pharmacokinetics
14%
High-risk Women
14%
U.S. Food
14%
HIV Infection
14%
Behavioral Characteristics
14%
HIV Prevention
14%
Medical History
14%
Truvada
14%
Health Traits
14%
Transgender
14%
Renal Safety
14%
Biological Characteristics
14%
Population at Risk
14%
Tenofovir Disoproxil Fumarate
14%
Evidence-based Algorithm
14%
HIV Acquisition
14%
Cisgender
14%
Emtricitabine
14%
Pharmacology, Toxicology and Pharmaceutical Science
HIV
100%
Emtricitabine
33%
Human Immunodeficiency Virus Infection
16%
Medical History
16%
Emtricitabine Plus Tenofovir Disoproxil
16%
Tenofovir Disoproxil
16%
Medicine and Dentistry
Emtricitabine
28%
Emtricitabine Plus Tenofovir Alafenamide
14%
Tenofovir Disoproxil
14%
Tenofovir Alafenamide
14%
Emtricitabine Plus Tenofovir Disoproxil
14%